{
  "query": "[Company name] AML compliance issues",
  "timestamp": "2025-09-06 08:21:47",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "re capital and as the proposed \namendments are approved by at least eighty-five \nper cent (85%) of the votes cast. (x) Powers of the board of directors to issue \nor to redeem the companys own shares \nAs of 31 December 2023, the Board of Directors \nwas authorized to issue new shares or redeem \nthe Companys own shares. In this respect, article 6 of the Companys Articles of Association \nprovide the following: Article 6: The Board of Directors shall have the power to \nincrease the Company's share capital, to issue \nconvertible bonds or subscription rights, in one \nor more operations, within the legal limits in \nterms of threshold and duration.",
      "similarity_score": 0.0588112746762019,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 349,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "d the \ninvestment of excess liquidity. The Group's \nTreasury identifies, assesses and covers \nfinancial risks in close cooperation with the \nCompany. More details on the management of financial \nrisks are available in the chapter FINANCIAL \nRISKS (ARTICLES 3: 6, 1, 8 AND 3:32, 1, 5, OF THE BCAC) of the consolidated financial \nstatements, see page 162. Significants acquisitions and divestments in \n2023 \nIn Febrary 2023, the group acquired Fluidomica \nLD.A. This entity produces Target Solutions for \nMedical Radioisopes Market. IBA also acquired a minority stake in Invest.BW \nS.A, a venture capital partner supporting the \neconomic development in the Walloon Region.",
      "similarity_score": 0.05710102975826844,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 561,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "ackage or services to a customer which comprises the \nequipment, installation and an agreed number of years of operation and maintenance of the site. The allocation of the price \nto the performance obligations is done based on the standard selling price of each component, driven by budget and taking \ninto accounts some contract negotiation considerations. IBAs contract with the customers typically does not contain \nvariable amounts and the financing component is also considered to be non-significant as milestones payments are spread \nover the project and reflect the progress of IBA in fulfilling its obligations.",
      "similarity_score": 0.06635114908955131,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 726,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "eener \nsterilization solutions, illustrating its importance \nalongside the more traditional ethylene oxide- \nand gamma-based sterilization solutions. This \nshift will be further boosted by more in-house \nsterilization sites operated by the sectors major \nplayers, thanks to the increased simplicity and \nreliability of IBAs technology. Industrial Solutions continues to investigate new \nopportunities, such \nas \nenvironmental \napplications to treat PFAS (forever chemicals) \nand wastewater. RadioPharma Solutions continues to provide \nmarket-leading support for radiopharmaceutical",
      "similarity_score": 0.05337573080559021,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 205,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "inly related to the change of \nworking capital for EUR -16.9 million and the \nnet loss of EUR -9.1 million; Negative financing cash-flow of EUR -14.4 \nmillion \nrelated \nto \nthe \nrepayment \nof \nborrowings and lease liabilities for EUR -7.5 \nmillion (mainly lease liabilities), the dividend \npaid for EUR -6.1 million and; Negative investing cash-flow of EUR -13.3 \nmillion mainly related to acquisitions of \ntangible and intangible assets of EUR -12.3 \nmillion and the convertible loan issued to \nPanTera for EUR -1.0 million. Net financial cash decreased by EUR -49.8 \nmillion from EUR 117.5 million at the end of 2022 \nto EUR 67.7 million at the end of 2023.",
      "similarity_score": 0.056125285241203124,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 522,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}